Summit Therapeutics PLC (SMMT NASDAQ) stock market data APIs
$21.341
-0.47(-2.2%)
as of June 30, 2025
Try our APIs with
free plan!
Summit Therapeutics PLC Financial Data Overview
Price chart is built with
Anychart
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis, as well as in Phase III clinical trials for the treatment of non-small lung cancer. The company was founded in 2003 and is headquartered in Miami, Florida.
Prev. Close
21.341
Open
20.8757
High
21.2292
Low
20.1919
52 wk Range
6.78-36.91
Market Cap
15 804 M
Shares Outstanding
743 M
EPS
-0.0677
Beta
-1.048
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Summit Therapeutics PLC data using free add-ons & libraries
Get Summit Therapeutics PLC Fundamental Data
Summit Therapeutics PLC Fundamental data includes:
- Net Revenue:
- EBITDA: -235 366 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-04-29
- EPS/Forecast: -0.0682
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Summit Therapeutics PLC News
New
Summit Therapeutics stock initiated with Buy rating at UBS on cancer drug potential
Investing.com - UBS initiated coverage on Summit Therapeutics plc (NASDAQ:SMMT) with a Buy rating and a $30.00 price target, citing the potential of its lead cancer drug candidate. The stock, currentl...
Summit Therapeutics stock initiated with Buy rating at Clear Street
Investing.com - Summit Therapeutics plc (NASDAQ:SMMT) received a Buy rating initiation from Clear Street with a price target of $30.00. According to InvestingPro data, analyst targets for the stock ra...
Revolution Medicines and Summit Therapeutics in-pact for cancer treatments
[Cancer cells vis] koto_feja/E+ via Getty Images * Revolution Medicines (NASDAQ:RVMD [https://seekingalpha.com/symbol/RVMD]) and Summit Therapeutics (NASDAQ:SMMT [https://seekingalpha.com/symbol/SM...
Revolution Medicines, Summit Therapeutics Enter Clinical Collaboration
(RTTNews) - Revolution Medicines, Inc. (RVMD) and Summit Therapeutics, Inc. (SMMT) have entered into a clinical collaboration in multiple solid tumor settings to evaluate the safety and efficacy of ea...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
